Wegovy Tablets - Definitive Guide

Wegovy tablets refer to a tablet form of semaglutide designed to support weight loss.

Semaglutide belongs to a group of medicines called GLP-1 receptor agonists. These medicines mimic a hormone in the body that helps regulate appetite and blood sugar levels.

Wegovy injections already use semaglutide and are widely prescribed in many countries for weight management. The tablet version contains the same active ingredient but is taken by mouth rather than injected under the skin.

In the United States, some people refer to these treatments as “Wegovy pills”. In the UK, the term “tablets” is more commonly used.

The tablet form is designed to offer another way of taking semaglutide for people who prefer not to use injections.

Wegovy tablets work in the same general way as Wegovy injections because they contain the same active ingredient, semaglutide.

Semaglutide mimics a naturally occurring hormone in the body called GLP-1 (glucagon-like peptide-1). This hormone plays an important role in regulating appetite and blood sugar levels.

GLP-1 medicines help with weight loss by:

• reducing appetite
• helping you feel full sooner during meals
• helping you stay full for longer after eating
• reducing cravings and “food noise”

These effects can make it easier to eat fewer calories and maintain a calorie deficit, which is necessary for weight loss.

As with injections, semaglutide tablets are intended to be used alongside healthy lifestyle changes such as improved diet and regular physical activity.

Wegovy tablets are not currently available in the UK for weight loss treatment.

Before any new medication can be offered in the UK, it must first be approved by the Medicines and Healthcare products Regulatory Agency. This process ensures that the medicine is safe, effective, and manufactured to appropriate standards.

Although semaglutide tablets are already available for treating type 2 diabetes under the brand name Rybelsus, the higher doses used for weight loss have not yet been approved in the UK for obesity treatment.

This means that people in the UK who want to use semaglutide for weight loss currently need to use the injection form.

It is not yet confirmed when semaglutide tablets for weight loss will become available in the UK. It could be as early as Summer 2026, and many professionals expect it to be available in the UK before the end of the year.

Clinical trials investigating tablet forms of semaglutide for obesity treatment have already been completed, and the results suggest they can support meaningful weight loss.

If the manufacturer submits the medication for regulatory approval, it will then need to be reviewed by the UK medicines regulator before it can be prescribed.

New weight loss medications are often introduced first through private clinics before becoming available more widely. If approved, tablets may initially be offered through private providers while national treatment guidelines are developed.

For now, Wegovy injections and other GLP-1 medicines remain the main options available for weight loss treatment in the UK.

Clinical studies suggest that semaglutide tablets can lead to significant weight loss compared with a placebo.

In one large study lasting 64 weeks, participants taking the highest dose of semaglutide tablets experienced an average weight loss of around 14% of their starting body weight.

The results showed that:

• around 75% participants lost at least 5% of their starting weight
• around 60% lost at least 10%
• around 47% lost at least 15%
• around 28% lost at least 20%

These results suggest that tablet forms of semaglutide can be an effective option for supporting weight loss.

However, studies of injectable semaglutide have generally shown slightly greater average weight loss than the tablet version.

Both Wegovy tablets and Wegovy injections contain semaglutide and work in similar ways in the body.

The main difference is how the medication is taken.

For some people, a daily tablet may feel easier than giving themselves an injection. Others may prefer a weekly injection so they do not need to take medication every day.

Both options aim to help people reduce appetite and achieve meaningful weight loss when combined with lifestyle changes.

In terms of effectiveness, clinical studies have shown that the highest dose of Wegovy injections can help facilitate weight loss of up to 20.7%, and Wegovy tablets have helped participants achieve an average of 14% weight loss.

Several medications are used in the UK to support weight loss. These include injectable treatments and tablets that work in different ways.

Mounjaro is another injectable medication used for weight loss. It works by activating two hormones involved in appetite regulation. Clinical trials suggest that the highest doses can produce greater average weight loss than semaglutide tablets.

Orlistat is a tablet that works differently. Instead of affecting appetite, it reduces the amount of fat absorbed from food. Weight loss with orlistat is generally more modest.

Mysimba is another tablet treatment that affects appetite and food cravings through the brain’s reward pathways. Average weight loss is typically lower than that seen in GLP-1 medications.

Overall, GLP-1 medicines such as semaglutide tend to produce greater average weight loss than older weight loss tablets.

Semaglutide tablets are taken once a day.

To help the medication work properly, they are usually taken first thing in the morning on an empty stomach.

Typical guidance includes:

• swallowing the tablet whole
• taking it with a small amount of water
• waiting at least 30 minutes before eating or drinking anything else
• waiting before taking other medications

The dose is usually increased gradually over time. This allows the body to adjust to the medication and can help reduce the risk of side effects.

An example dosing schedule studied in trials includes starting on a low dose and increasing over several months until the maintenance dose is reached.

Because Wegovy tablets are not yet available in the UK, the exact doses that will eventually be offered have not been confirmed. However, clinical trials studying tablet forms of semaglutide give a good indication of the strengths that may be used.

In studies of oral semaglutide for weight loss, participants typically started on a low dose and gradually increased to a higher maintenance dose over several weeks. This gradual increase helps the body adjust to the medication and can reduce the likelihood of side effects.

The tablet doses studied in weight loss trials include:

• 1.5 mg
• 4 mg
• 9 mg
• 25 mg

In these studies, the lower doses are used at the beginning of treatment, with the dose increased roughly every four weeks until the maintenance dose is reached.

The 25 mg tablet has been the main dose studied for long-term weight management and has shown significant weight loss results in clinical trials when taken once daily.

Researchers have also investigated higher doses such as 50 mg in some studies to explore whether greater weight loss may be possible.

The final dosing schedule available to patients in the UK will depend on regulatory approval and manufacturer guidance. If approved, doctors would normally start patients on a low dose and gradually increase it until the most effective and well-tolerated dose is reached.

As with other GLP-1 medications, dose increases would always need to be guided by a healthcare professional.

Like all medications, semaglutide tablets can cause side effects in some people.

These side effects are usually mild and often improve as the body adjusts to the medication.

Common side effects reported in studies include:

• nausea
• vomiting
• diarrhoea
• constipation
• stomach discomfort
• bloating
• headache
• tiredness

Side effects are most common when first starting the medication or after increasing the dose.

If semaglutide tablets are approved in the UK for weight loss, full prescribing information will be provided with detailed safety guidance.

Final eligibility criteria for semaglutide tablets in the UK will depend on regulatory approval and prescribing guidelines.

However, it is likely that similar criteria to current GLP-1 treatments will apply.

These typically include:

• a body mass index (BMI) of 30 or higher
• a BMI of 27 or higher with a weight-related health condition such as high blood pressure

Doctors will also consider a person’s medical history, current medications, and overall health before prescribing treatment.

Semaglutide medications are not suitable for everyone, and a medical assessment is always required before starting treatment.

Wegovy injections are currently available on the NHS for some patients through specialist weight management services.

Access is limited and usually requires referral to a specialist programme.

If semaglutide tablets are approved for weight loss in the UK, the NHS may eventually consider them as part of obesity treatment pathways.

However, many people currently access GLP-1 medications through private providers due to the limited availability of NHS programmes.

The price of semaglutide tablets for weight loss in the UK has not yet been announced.

Pricing will depend on factors such as regulatory approval, manufacturer pricing, and how the medication is supplied through healthcare providers.

For context, current GLP-1 weight loss injections in the UK typically cost between around £100 and £250 per month depending on the dose and provider.

If tablets become available, the price may fall within a similar range – and potentially slightly lower – although this cannot yet be confirmed.

In the USA, Wegovy tablets are usually $149 – $299 per month (self-pay, depending on dose), compared to injections which are often $199-$349 per month (self-pay, depending on dose).